Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

PINP: a serum biomarker of bone formation in the rat.

Hale LV, Galvin RJ, Risteli J, Ma YL, Harvey AK, Yang X, Cain RL, Zeng Q, Frolik CA, Sato M, Schmidt AL, Geiser AG.

Bone. 2007 Apr;40(4):1103-9. Epub 2006 Dec 22.

PMID:
17258520
2.

Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.

Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, Frolik CA, Engler T, Wei T, Kriauciunas A, Martin TJ, Sato M, Bryant HU, Ma YL.

J Bone Miner Res. 2006 Jun;21(6):910-20.

3.

Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.

Helvering LM, Liu R, Kulkarni NH, Wei T, Chen P, Huang S, Lawrence F, Halladay DL, Miles RR, Ambrose EM, Sato M, Ma YL, Frolik CA, Dow ER, Bryant HU, Onyia JE.

Mol Pharmacol. 2005 Nov;68(5):1225-38. Epub 2005 Aug 3.

PMID:
16079270
4.

Effects of parathyroid hormone on Wnt signaling pathway in bone.

Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE.

J Cell Biochem. 2005 Aug 15;95(6):1178-90.

PMID:
15962290
5.

High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells.

Borchert KM, Galvin RJ, Frolik CA, Hale LV, Halladay DL, Gonyier RJ, Trask OJ, Nickischer DR, Houck KA.

Assay Drug Dev Technol. 2005 Apr;3(2):133-41.

PMID:
15871688
6.

Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray.

Onyia JE, Helvering LM, Gelbert L, Wei T, Huang S, Chen P, Dow ER, Maran A, Zhang M, Lotinun S, Lin X, Halladay DL, Miles RR, Kulkarni NH, Ambrose EM, Ma YL, Frolik CA, Sato M, Bryant HU, Turner RT.

J Cell Biochem. 2005 May 15;95(2):403-18.

PMID:
15779007
7.

Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure.

Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M, Hock JM.

Bone. 2003 Sep;33(3):372-9.

PMID:
13678779
8.

Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling.

Krishnan V, Moore TL, Ma YL, Helvering LM, Frolik CA, Valasek KM, Ducy P, Geiser AG.

Mol Endocrinol. 2003 Mar;17(3):423-35. Epub 2002 Dec 18.

PMID:
12554794
9.

Parathyroid hormone-(1-34) enhances aggrecan synthesis via an insulin-like growth factor-I pathway.

Harvey AK, Yu XP, Frolik CA, Chandrasekhar S.

J Biol Chem. 1999 Aug 13;274(33):23249-55.

10.
11.

Development of a scintillation proximity assay for high-throughput measurement of intact parathyroid hormone.

Frolik CA, Black EC, Chandrasekhar S, Adrian MD.

Anal Biochem. 1998 Dec 15;265(2):216-24.

PMID:
9882395
12.

Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.

Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, Spangle LA, Martin MJ, Phillips DL, Glasebrook AL, Osborne JJ, Frolik CA, Bryant HU.

J Steroid Biochem Mol Biol. 1997 Apr;61(1-2):97-106.

PMID:
9328215
13.

Structure and functional expression of a complementary DNA for porcine parathyroid hormone/parathyroid hormone-related peptide receptor.

Smith DP, Zhang XY, Frolik CA, Harvey A, Chandrasekhar S, Black EC, Hsiung HM.

Biochim Biophys Acta. 1996 Jul 17;1307(3):339-47.

PMID:
8688470
14.
15.
16.

NMR studies of the active site of isopenicillin N synthase, a non-heme iron(II) enzyme.

Ming LJ, Que L Jr, Kriauciunas A, Frolik CA, Chen VJ.

Biochemistry. 1991 Dec 17;30(50):11653-9.

PMID:
1661145
17.

Binding of insulin-like growth factors to Tera-2 human embryonal carcinoma cells during differentiation.

Fleck JF, Sledge GW Jr, Benenati SV, Frolik CA, Roth BJ, Hirsch KS.

Cancer Res. 1991 Aug 15;51(16):4395-401.

18.

Binding of insulin-like growth factors to cultured rat calvarial cells with differing biologic responses.

Cantrell PR, Frolik CA, Ellis LF, Williams DC.

J Bone Miner Res. 1991 Aug;6(8):851-7.

PMID:
1664647
19.

The functional role of cysteines in isopenicillin N synthase. Correlation of cysteine reactivities toward sulfhydryl reagents with kinetic properties of cysteine mutants.

Kriauciunas A, Frolik CA, Hassell TC, Skatrud PL, Johnson MG, Holbrook NL, Chen VJ.

J Biol Chem. 1991 Jun 25;266(18):11779-88.

20.

Physiological and pharmacological regulation of biological calcification.

Williams DC, Frolik CA.

Int Rev Cytol. 1991;126:195-292. Review.

PMID:
2050499
21.

Spectroscopic studies of isopenicillin N synthase. A mononuclear nonheme Fe2+ oxidase with metal coordination sites for small molecules and substrate.

Chen VJ, Orville AM, Harpel MR, Frolik CA, Surerus KK, Münck E, Lipscomb JD.

J Biol Chem. 1989 Dec 25;264(36):21677-81.

22.

Cloning and expression in Escherichia coli of isopenicillin N synthetase genes from Streptomyces lipmanii and Aspergillus nidulans.

Weigel BJ, Burgett SG, Chen VJ, Skatrud PL, Frolik CA, Queener SW, Ingolia TD.

J Bacteriol. 1988 Sep;170(9):3817-26.

23.

Isolation and characterization of insulin-like growth factor-II from human bone.

Frolik CA, Ellis LF, Williams DC.

Biochem Biophys Res Commun. 1988 Mar 30;151(3):1011-8.

PMID:
3162675
24.

Radioreceptor assays for transforming growth factors.

Frolik CA, De Larco JE.

Methods Enzymol. 1987;146:95-102. No abstract available.

PMID:
3479676
26.

Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts.

Frolik CA, Wakefield LM, Smith DM, Sporn MB.

J Biol Chem. 1984 Sep 10;259(17):10995-1000.

27.

Inhibition of transforming growth factor-induced cell growth in soft agar by oxidized polyamines.

Frolik CA, Roller PP, Cone JL, Dart LL, Smith DM, Sporn MB.

Arch Biochem Biophys. 1984 Apr;230(1):93-102.

PMID:
6585180
28.

Transforming growth factor-beta controls receptor levels for epidermal growth factor in NRK fibroblasts.

Assoian RK, Frolik CA, Roberts AB, Miller DM, Sporn MB.

Cell. 1984 Jan;36(1):35-41.

PMID:
6319010
29.

Purification and initial characterization of a type beta transforming growth factor from human placenta.

Frolik CA, Dart LL, Meyers CA, Smith DM, Sporn MB.

Proc Natl Acad Sci U S A. 1983 Jun;80(12):3676-80.

30.

Transforming growth factors from neoplastic and nonneoplastic tissues.

Roberts AB, Frolik CA, Anzano MA, Sporn MB.

Fed Proc. 1983 Jun;42(9):2621-6.

PMID:
6303865
31.

Variables in the high-pressure cation-exchange chromatography of proteins.

Frolik CA, Dart LL, Sporn MB.

Anal Biochem. 1982 Sep 1;125(1):203-9. No abstract available.

PMID:
6816090
32.

Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF.

Roberts AB, Anzano MA, Lamb LC, Smith JM, Frolik CA, Marquardt H, Todaro GJ, Sporn MB.

Nature. 1982 Feb 4;295(5848):417-9. No abstract available.

PMID:
6276769
33.

Metabolism of 13-cis-retinoic acid: identification of 13-cis-retinoyl- and 13-cis-4-oxoretinoyl-beta-glucuronides in the bile of vitamin A-normal rats.

Frolik CA, Swanson BN, Dart LL, Sporn MB.

Arch Biochem Biophys. 1981 May;208(2):344-52. No abstract available.

PMID:
6942787
34.

In vitro and in vivo metabolism of all-trans- and 13-cis-retinoic acid in the hamster.

Frolik CA.

Ann N Y Acad Sci. 1981 Feb 27;359:37-44. No abstract available.

PMID:
6942683
35.

Metabolism of all-trans-retinyl acetate to retinoic acid in hamster tracheal organ culture.

Frolik CA, Dart LL, Sporn MB.

Biochim Biophys Acta. 1981 Jan 26;663(1):329-35.

PMID:
7213770
36.

Dose-dependent kinetics of all-trans-retinoic acid in rats. Plasma levels and excretion into bile, urine, and faeces.

Swanson BN, Frolik CA, Zaharevitz DW, Roller PP, Sporn MB.

Biochem Pharmacol. 1981 Jan 15;30(2):107-13. No abstract available.

PMID:
7236299
37.
38.

Recent advances in the in vivo and in vitro metabolism of retinoic acid.

Roberts AB, Frolik CA.

Fed Proc. 1979 Oct;38(11):2524-7.

PMID:
488375
39.

Retinoid-dependent induction of the in vivo and in vitro metabolism of retinoic acid in tissues of the vitamin A-deficient hamster.

Roberts AB, Frolik CA, Nichols MD, Sporn MB.

J Biol Chem. 1979 Jul 25;254(14):6303-9. No abstract available.

40.

Isolation and identification of 4-hydroxy- and 4-oxoretinoic acid. In vitro metabolites of all-trans-retinoic acid in hamster trachea and liver.

Frolik CA, Roberts AB, Tavela TE, Roller PP, Newton DL, Sporn MB.

Biochemistry. 1979 May 15;18(10):2092-7.

PMID:
435468
41.

In vitro metabolism and biological activity of all-trans-retinoic acid and its metabolites in hamster trachea.

Frolik CA, Tavela TE, Newton DL, Sporn MB.

J Biol Chem. 1978 Oct 25;253(20):7319-24.

42.

Assay of retinoids in biological samples by reverse-phase high-pressure liquid chromatography.

Roberts AB, Nichols MD, Frolik CA, Newton DL, Sporn MB.

Cancer Res. 1978 Oct;38(10):3327-32.

43.

High-pressure liquid chromatographic determination of 13-cis-retinoic acid and all-trans-retinoic acid in human plasma.

Frolik CA, Tavela TE, Peck GL, Sporn MB.

Anal Biochem. 1978 Jun 1;86(2):743-50. No abstract available.

PMID:
655427
44.

Biological activity and metabolism of the retinoid axerophthene (vitamin A hydrocarbon).

Newton DL, Frolik CA, Roberts AB, Smith JM, Sporn MB, Nürrenbach A, Paust J.

Cancer Res. 1978 Jun;38(6):1734-8.

45.

Separation of the natural retinoids by high-pressure liquid chromatography.

Frolik CA, Tavela TE, Sporn MB.

J Lipid Res. 1978 Jan;19(1):32-7.

47.

Solubilization and partial purification of a rat intestinal 1,25-dihydroxyvitamin D3 binding protein.

Frolik CA, DeLuca HF.

Steroids. 1975 Nov;26(5):683-5. No abstract available.

PMID:
1209692
49.

Metabolism of 1,25-dihydroxycholecalciferol in the rat.

Frolik CA, DeLuca HF.

J Clin Invest. 1972 Nov;51(11):2900-6.

50.

1,25-dihydroxycholecalciferol: the metabolite of vitamin D responsible for increased intestinal calcium transport.

Frolik CA, Deluca HF.

Arch Biochem Biophys. 1971 Nov;147(1):143-7. No abstract available.

PMID:
4329860

Supplemental Content

Loading ...
Support Center